Intravenous administration of Cosentyx is approved for adult patients only as the safety and effectiveness of this formulation in pediatric patients have not been established.

For HS, Cosentyx is administered as a subcutaneous injection. The product is available in single-dose pens or prefilled syringes.

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company’s efforts to find new uses for the ...

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press ...

The approval makes Cosentyx (secukinumab) the first interleukin-17A inhibitor approved for the treatment of hidradenitis suppurativa (HS) and the second biologic approved for this indication.

Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis.

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.

The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of secukinumab (Cosentyx) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new ...